212 related articles for article (PubMed ID: 36377597)
1. Integrated analysis of the genomic and transcriptional profile of gliomas with isocitrate dehydrogenase-1 and tumor protein 53 mutations.
Liu HQ; Li WX; An YW; Wu T; Jiang GY; Dong Y; Chen WX; Wang JC; Wang C; Song S
Int J Immunopathol Pharmacol; 2022; 36():3946320221139262. PubMed ID: 36377597
[No Abstract] [Full Text] [Related]
2. RARRES2 is Downregulated in Isocitrate Dehydrogenase 1 Mutant Glioma Patients and Served as an Unfavorable Prognostic Factor of Glioma.
Wang H; Wang X; Xu L; Zhang J
World Neurosurg; 2023 Aug; 176():e610-e622. PubMed ID: 37271257
[TBL] [Abstract][Full Text] [Related]
3. Gene Expression Profiling Stratifies IDH1-Mutant Glioma with Distinct Prognoses.
Cheng W; Ren X; Zhang C; Cai J; Han S; Wu A
Mol Neurobiol; 2017 Oct; 54(8):5996-6005. PubMed ID: 27696222
[TBL] [Abstract][Full Text] [Related]
4. Mutant IDH1 and thrombosis in gliomas.
Unruh D; Schwarze SR; Khoury L; Thomas C; Wu M; Chen L; Chen R; Liu Y; Schwartz MA; Amidei C; Kumthekar P; Benjamin CG; Song K; Dawson C; Rispoli JM; Fatterpekar G; Golfinos JG; Kondziolka D; Karajannis M; Pacione D; Zagzag D; McIntyre T; Snuderl M; Horbinski C
Acta Neuropathol; 2016 Dec; 132(6):917-930. PubMed ID: 27664011
[TBL] [Abstract][Full Text] [Related]
5. Association of
Murnyak B; Huang LE
Cells; 2021 Aug; 10(8):. PubMed ID: 34440884
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.
Takahashi Y; Nakamura H; Makino K; Hide T; Muta D; Kamada H; Kuratsu J
World J Surg Oncol; 2013 Oct; 11():284. PubMed ID: 24160898
[TBL] [Abstract][Full Text] [Related]
7. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
[TBL] [Abstract][Full Text] [Related]
8. PCR-Based Simple Subgrouping Is Validated for Classification of Gliomas and Defines Negative Prognostic Copy Number Aberrations in IDH Mutant Gliomas.
Nakae S; Sasaki H; Hayashi S; Hattori N; Kumon M; Nishiyama Y; Adachi K; Nagahisa S; Hayashi T; Inamasu J; Abe M; Hasegawa M; Hirose Y
PLoS One; 2015; 10(11):e0142750. PubMed ID: 26558387
[TBL] [Abstract][Full Text] [Related]
9. IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response.
Núñez FJ; Mendez FM; Kadiyala P; Alghamri MS; Savelieff MG; Garcia-Fabiani MB; Haase S; Koschmann C; Calinescu AA; Kamran N; Saxena M; Patel R; Carney S; Guo MZ; Edwards M; Ljungman M; Qin T; Sartor MA; Tagett R; Venneti S; Brosnan-Cashman J; Meeker A; Gorbunova V; Zhao L; Kremer DM; Zhang L; Lyssiotis CA; Jones L; Herting CJ; Ross JL; Hambardzumyan D; Hervey-Jumper S; Figueroa ME; Lowenstein PR; Castro MG
Sci Transl Med; 2019 Feb; 11(479):. PubMed ID: 30760578
[TBL] [Abstract][Full Text] [Related]
10. Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?
Kloosterhof NK; Bralten LB; Dubbink HJ; French PJ; van den Bent MJ
Lancet Oncol; 2011 Jan; 12(1):83-91. PubMed ID: 20615753
[TBL] [Abstract][Full Text] [Related]
11. IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas.
Shibahara I; Sonoda Y; Kanamori M; Saito R; Yamashita Y; Kumabe T; Watanabe M; Suzuki H; Kato S; Ishioka C; Tominaga T
Int J Clin Oncol; 2012 Dec; 17(6):551-61. PubMed ID: 21971842
[TBL] [Abstract][Full Text] [Related]
12. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
13. IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma.
Zhang C; Moore LM; Li X; Yung WK; Zhang W
Neuro Oncol; 2013 Sep; 15(9):1114-26. PubMed ID: 23877318
[TBL] [Abstract][Full Text] [Related]
14. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups.
Weller M; Weber RG; Willscher E; Riehmer V; Hentschel B; Kreuz M; Felsberg J; Beyer U; Löffler-Wirth H; Kaulich K; Steinbach JP; Hartmann C; Gramatzki D; Schramm J; Westphal M; Schackert G; Simon M; Martens T; Boström J; Hagel C; Sabel M; Krex D; Tonn JC; Wick W; Noell S; Schlegel U; Radlwimmer B; Pietsch T; Loeffler M; von Deimling A; Binder H; Reifenberger G
Acta Neuropathol; 2015 May; 129(5):679-93. PubMed ID: 25783747
[TBL] [Abstract][Full Text] [Related]
15. EZH2-, CHD4-, and IDH-linked epigenetic perturbation and its association with survival in glioma patients.
Zhang L; Liu Y; Wang M; Wu Z; Li N; Zhang J; Yang C
J Mol Cell Biol; 2017 Dec; 9(6):477-488. PubMed ID: 29272522
[TBL] [Abstract][Full Text] [Related]
16. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
Paul Y; Mondal B; Patil V; Somasundaram K
Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
[TBL] [Abstract][Full Text] [Related]
17. MUC16 mutation is associated with tumor grade, clinical features, and prognosis in glioma patients.
Ferrer VP
Cancer Genet; 2023 Jan; 270-271():22-30. PubMed ID: 36436416
[TBL] [Abstract][Full Text] [Related]
18. Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas.
Chou AP; Chowdhury R; Li S; Chen W; Kim AJ; Piccioni DE; Selfridge JM; Mody RR; Chang S; Lalezari S; Lin J; Sanchez DE; Wilson RW; Garrett MC; Harry B; Mottahedeh J; Nghiemphu PL; Kornblum HI; Mischel PS; Prins RM; Yong WH; Cloughesy T; Nelson SF; Liau LM; Lai A
J Natl Cancer Inst; 2012 Oct; 104(19):1458-69. PubMed ID: 22945948
[TBL] [Abstract][Full Text] [Related]
19. Expression and prognostic value of microRNAs in lower-grade glioma depends on IDH1/2 status.
Cheng W; Ren X; Zhang C; Han S; Wu A
J Neurooncol; 2017 Apr; 132(2):207-218. PubMed ID: 28091987
[TBL] [Abstract][Full Text] [Related]
20. BRAF
Wang W; Wang M; Jiang H; Wang T; Da R
BMC Neurol; 2021 May; 21(1):195. PubMed ID: 33980169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
